Research programme: infectious diseases therapeutic vaccines - Vakzine Project Management

Drug Profile

Research programme: infectious diseases therapeutic vaccines - Vakzine Project Management

Alternative Names: DB; MSP-1/HD-1 adjuvant; rBCGΔUreC:Hly; VPM 2001

Latest Information Update: 29 Jul 2016

Price : $50

At a glance

  • Originator Vakzine Projekt Management
  • Developer Rhein Biotech; Vakzine Projekt Management
  • Class Bacterial vaccines; Tuberculosis vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cytomegalovirus infections
  • Discontinued Malaria; Tuberculosis

Most Recent Events

  • 29 Jul 2016 Discontinued - Preclinical for Tuberculosis in Germany (unspecified route)
  • 29 Jul 2016 Discontinued - Preclinical for Malaria in Germany (IM)
  • 29 Jul 2016 Preclinical development is ongoing for Cytomegalovirus infections in Germany (Vakzine Projekt Management pipeline, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top